Severe oral mucositis and healthcare utilization in adults with acute lymphoblastic leukemia receiving myeloablative total body irradiation–based conditioning

PURPOSE: We evaluated the association between total body irradiation (TBI) dose and severe oral mucositis (OM) in adults with acute lymphoblastic leukemia (ALL) undergoing myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: We analyzed 101 adults receiving 8 or 12 Gy TBI. Severe OM was defined as WHO grades 3-4. TBI allocation was non-randomized, with 8 Gy more frequently used in older patients and those with a Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) > 3. Multivariable logistic regression assessed factors associated with severe OM, with the Karnofsky Performance Status (KPS) included in the primary model; sensitivity analyses evaluated alternative models. RESULTS: Severe OM occurred in 48 patients (47.5%) and was more frequent after 12 than 8 Gy (62.0% vs. 33.3%, P = 0.005). In the primary model, 12 Gy TBI was associated with higher odds of severe OM (OR 2.78, 95% CI 1.17-6.78; P = 0.022). The association between 12 Gy TBI and severe OM remained significant when HCT-CI replaced KPS and after calendar-year adjustment. After age adjustment, the estimate was similar, but the confidence interval widened and included the null (OR 2.63, 95% CI 0.90-8.06; P = 0.081). Severe OM was associated with a 4-day longer median hospital stay (41 vs. 37 days, P = 0.001) and a 5-day longer median duration of systemic therapeutic antibiotic treatment (20 vs. 15 days, P = 0.002). Neither measure differed significantly by TBI dose. CONCLUSION: Higher TBI dose was associated with severe OM; severe OM was associated with longer hospital stays and systemic therapeutic antibiotic treatment. Findings should be interpreted cautiously given non-randomized TBI allocation. CLINICAL TRIAL REGISTRATION: This study is a retrospective analysis and was not registered as a clinical trial.

Authors

Institutions

Publication Details

Journal
Supportive Care in Cancer
Published
2026-11-18
DOI
https://doi.org/10.1007/s00520-026-11471-7
Primary Topic
Oral health in cancer treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Severe oral mucositis and healthcare utilization in adults with acute lymphoblastic leukemia receiving myeloablative total body irradiation–based conditioning

Isabella Gruber, Ernst Holler, Daniel Wolff, Elisabeth Meedt et al.
6 links
Supportive Care in Cancer
Oral health in cancer treatment
article

Severe oral mucositis and healthcare utilization in adults with acute lymphoblastic leukemia receiving myeloablative total body irradiation–based conditioning

Isabella Gruber, Ernst Holler, Daniel Wolff, Elisabeth Meedt, Hendrik Poeck, Daniela Weber, Oliver Koelbl, Matthias Edinger, Wolfgang Herr
article en

Abstract

PURPOSE: We evaluated the association between total body irradiation (TBI) dose and severe oral mucositis (OM) in adults with acute lymphoblastic leukemia (ALL) undergoing myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: We analyzed 101 adults receiving 8 or 12 Gy TBI. Severe OM was defined as WHO grades 3-4. TBI allocation was non-randomized, with 8 Gy more frequently used in older patients and those with a Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) > 3. Multivariable logistic regression assessed factors associated with severe OM, with the Karnofsky Performance Status (KPS) included in the primary model; sensitivity analyses evaluated alternative models. RESULTS: Severe OM occurred in 48 patients (47.5%) and was more frequent after 12 than 8 Gy (62.0% vs. 33.3%, P = 0.005). In the primary model, 12 Gy TBI was associated with higher odds of severe OM (OR 2.78, 95% CI 1.17-6.78; P = 0.022). The association between 12 Gy TBI and severe OM remained significant when HCT-CI replaced KPS and after calendar-year adjustment. After age adjustment, the estimate was similar, but the confidence interval widened and included the null (OR 2.63, 95% CI 0.90-8.06; P = 0.081). Severe OM was associated with a 4-day longer median hospital stay (41 vs. 37 days, P = 0.001) and a 5-day longer median duration of systemic therapeutic antibiotic treatment (20 vs. 15 days, P = 0.002). Neither measure differed significantly by TBI dose. CONCLUSION: Higher TBI dose was associated with severe OM; severe OM was associated with longer hospital stays and systemic therapeutic antibiotic treatment. Findings should be interpreted cautiously given non-randomized TBI allocation. CLINICAL TRIAL REGISTRATION: This study is a retrospective analysis and was not registered as a clinical trial.

Supportive Care in CancerVol. 34(12)
University Hospital Regensburg (DE), Leibniz Institute for Immunotherapy (DE)
Universitätsklinikum Regensburg
Good health and well-being
Oral health in cancer treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon